A Study to Evaluate the Efficacy and Safety of AD-209
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 221 participants.
Also called NCT05631990
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 221 participants
- Sponsor
- Registry
-
NCT05631990
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT05631990. Randomized; double masking; primary purpose treatment. Start 2023-04-05 (actual); primary completion 2023-11-27 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Efficacy and Safety of AD-209
- Condition
- Hypertension, Essential
- Intervention (Drug)
- AD-209
- Intervention (Drug)
- AD-209-1A
- Intervention (Drug)
- AD-209-1B
- Intervention (Drug)
- AD-209-1C
- Intervention (Drug)
- AD-209 placebo
- Intervention (Drug)
- AD-209-1 placebo
- Lead sponsor
- Addpharma Inc.
Record details
- Record id
cardio:ct-nct05631990- Content hash
b22168553b6be5622c23f41d6fbf14c0af5c174c12d3da143a984d878d782ee5